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ABSTRACT
In kidney transplant patients with BK polyomavirus (BKPyV) nephropathy, viral variants arise bearing rearranged non-
coding control regions (rr-NCCRs) that increase viral early gene expression, replicative fitness, and cytopathology.
rr-NCCRs result from various deletions and duplications of archetype NCCR (ww-NCCR) sequences, which alter tran-
scription factor binding sites (TFBS). However, the role of specific TFBS is unclear. We inactivated 28 TFBS in the arche-
type NCCR by selective point mutations and examined viral gene expression in bidirectional reporter constructs. Com-
pared to the archetype, group 1 mutations increased viral early gene expression similar to rr-NCCR and resulted from
inactivating one Sp1 or one Ets1 TFBS near the late transcription start site (TSS). Group 2 mutations conferred intermedi-
ate early gene activation and affected NF1, YY1, and p53 sites between early and late TSS. Group 3 mutations decreased
early and late gene expression and included two other Sp1 sites near the early TSS. Recombinant viruses bearing group 1
NCCRs showed increased replication in human renal epithelial cells similar to clinical rr-NCCR variants. Group 2 and 3
viruses showed intermediate or no replication, respectively. A literature search revealed unnoticed group 1 mutations in
BKPyV nephropathy, hemorrhagic cystitis, and disseminated disease.
IMPORTANCE
The NCCRs of polyomaviruses mediate silent persistence of the viral genome as well as the appropriately timed (re)activation of
the viral life cycle. This study indicates that the basal BKPyVNCCR is critically controlled by a hierarchy of single TFBS in the
archetype NCCR that direct, modulate, and execute the bidirectional early and late viral gene expression. The results provide
new insights into how BKPyVNCCR functions as a viral sensor of host cell signals and shed new light on how transcription fac-
tors like Sp1 control bidirectional viral gene expression and contribute to replication and pathology.
BK polyomavirus (BKPyV) is one of now more than 12 humanPyVs (1) and is known to infect more than 90% of the human
population during early childhood (2–6). Following primary in-
fection, BKPyV persists latently in the renourinary tract, with in-
termittent periods of asymptomatic shedding into urine (5, 7).
BKPyV disease typically occurs in individuals with altered im-
mune functions, to which viral determinants are thought to con-
tribute (3, 8). Thus, BKPyV causes nephropathy in 1 to 14% of
kidney transplant patients and hemorrhagic cystitis in 5 to 20% of
allogeneic hematopoietic stem cell transplant recipients (2, 9).
BKPyV strains excreted in urine of healthy immunocompetent
individuals typically bear a noncoding control region (NCCR) of
linear archetype (ww) architecture (ww-NCCR) (5, 10, 11) and
grow slowly in primary human urothelial and renal tubular epi-
thelial cells (8, 12). In immunosuppressed kidney transplant pa-
tients with early stages of BKPyV-associated nephropathy, the vi-
rus contains mostly archetype ww-NCCR (8, 13). However, when
immunosuppression is not readily reduced to permit specific T
cells to resume control over BKPyV replication (14–17), viral vari-
ants with rearranged NCCRs (rr-NCCRs) emerge that are associ-
ated with higher plasma viral loads and more severe renal allograft
pathology (8). Similar rr-NCCRs of JC polyomavirus have been
linked with the emergence of progressive multifocal leukoenceph-
alopathy, a debilitating, often fatal brain disease in immunocom-
promised patients with HIV/AIDS or receiving transplantation or
therapies for cancer and immune diseases (18–22). The archetype
NCCR of polyomaviruses is approximately 400 bp in length and
harbors the origin of replication as well as bidirectional promoter/
enhancer functions that, in concert with the host cell signals, con-
trol the timing and sequential activation of early viral gene region
(EVGR) expression, viral DNA genome replication, and late viral
gene region (LVGR) expression. Notably, EVGR and LVGR are
encoded and transcribed in opposite directions from the
NCCR (23). The 2.3-kb EVGR encodes the small T antigen,
the large T antigen (LTag), and several splicing variants,
whereas the 2.5-kb LVGR encodes the capsid proteins VP1,
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VP2, and VP3 and, in the case of BKPyV and JCPyV, the small
nonstructural agnoprotein (2).
Sequencing of naturally occurring BKPyV rr-NCCRs variants
in kidney transplant patients revealed that the rearrangements
alter the number and composition of transcription factor binding
sites (TFBS) as a result of partial duplications and deletions of the
archetype sequence (8, 13, 24, 25). Phenotypic analysis using bi-
directional reporter constructs mimicking the polyomavirus ge-
nome organization indicated that the clinical rr-NCCR variants
constitutively activate EVGR expression compared to archetype
NCCR (8, 26). However, no common sequence or TFBS pat-
tern could be identified. To address the role of specific TFBS in
rr-NCCR of BKPyV, we chose a minimally disruptive approach by
introducing selective point mutations predicted to inactivate
TFBS without affecting the overall length or architecture of the
archetype ww-NCCR. The results indicate for the first time a hi-
erarchy of TFBS with at least three phenotypic groups. Group 1
mutants showed high early and low late gene expression, similar to
rr-NCCR emerging in vivo, and resulted from inactivating single
Sp1 and Ets1 sites close to the late transcription start site (TSS).
Group 2 and group 3 mutants showed intermediate and low gene
expression, respectively. In a database search, we identified corre-
sponding mutations in the BKPyV NCCRs from patients with
significant BKPyV pathology, such as nephropathy, hemorrhagic
cystitis, and disseminated infection, that had not been identified as
viral pathology determinants (27–29). Our results provide new
insights into how polyomavirus NCCRs function through specific
TFBS and shed new light on how Sp1 controls bidirectional
BKPyV gene expression and its role in BKPyV pathology.
MATERIALS AND METHODS
Prediction and mutation of potential TFBS. The DNA genome of the
archetype BKPyV ww(1.4) strain is 5,142 bp and contains the ww-NCCR
of 376 bp flanked by the EVGR start codon of LTag at 5142 bp and the
LVGR start codon of agnoprotein at 377 bp. The programs PROMO and
Alibaba2.1 were used to determine the locations of potential TFBS in the
ww-NCCR and in the rr-NCCR sequences of different variants with inter-
mediate stringency to get a good compromise between false and missing
predictions. The predicted TFBS were graphically depicted within the
OPQRS architecture (Fig. 1). Empirically, minimal transitions and trans-
versions were introduced into the predicted TFBS, and the potential effect
was analyzed using both programs. Mutations abrogating TFBS without
affecting neighboring TFBS were selected (Fig. 2A; also, see Table S1 in the
supplemental material), and the corresponding NCCRs were chemically
synthesized (Eurogentec, Belgium). Similarly, a selection of TFBS mu-
tants was placed into the del(R8–18) rr-NCCR background described pre-
viously (8), wherein an 11-bp sequence has been deleted from the R block
by site-directed mutagenesis, causing a small increase and decrease in
EVGR and LVGR, respectively (Fig. 2B). All final plasmid constructs were
verified by standard dideoxy sequencing.
Cell culture. Primary renal proximal tubule epithelial cells (RPTECs;
PCS-400-010; ATCC, Manassas, VA, USA) were grown in epithelial cell
medium (EpiCM; no. 4101; ScienceCell Research Laboratory, Carlsbad,
CA, USA) supplemented with epithelial cell growth supplement (EpiCGS,
no. 4152, ScienceCell Research Laboratory, Carlsbad, USA) and 2% fetal
bovine serum (FBS; no. 0010; ScienceCell Research Laboratory). HEK293
cells (CRL1573; ATCC) were propagated in Dulbecco’s modified Eagle’s
medium, high-glucose formulation (DMEM-H; D5671; Sigma-Aldrich,
St. Louis, MO, USA), containing 10% FBS (S0113; Biochrome AG, Berlin,
Germany). COS-7 cells (CRL1651; ATCC, Manassas, VA, USA) were
grown in DMEM-H containing 5% FBS. All cultures were supplemented
with 2 mM L-glutamine (K0302; Biochrome AG, Berlin, Germany).
FACS-based, bidirectional reporter assay.For the bidirectional reporter
assay, HEK293 cells were seeded in 12-well plates and transfected at 70 to 80%
confluence with Lipofectamine 2000 (11668-019; Invitrogen, Carlsbad, CA)
at a ratio of 3:1 (3l reagent and 1g plasmid DNA) in Opti-MEM (Gibco,
Grand Island, NY, USA) according to the manufacturers’ instructions. Me-
dium was replaced with DMEM-H–10% FBS the next morning. At 48 h
posttransfection, cells were rinsed once with PBS–2.5 mM EDTA and then
detached, suspended, and transferred to 5-ml polystyrene round-bottom flu-
orescence-activated-cell-sorting (FACS) tubes (BD, Franklin Lakes, NJ, USA)
with 1 ml PBS–2.5 mM EDTA. Directly before each measurement, DAPI
(D8417; Sigma-Aldrich, St. Louis, MO, USA) was added (final concentration,
1 ng/ml) as a dead-cell marker, and cells were resuspended. FACS measure-
ments were carried out on a Fortessa Cytometer (BD, Franklin Lakes,
NJ, USA) at medium flow with the following settings: forward scatter
(FSC) at 220 V, side scatter (SSC) at 220 V; GFP, excitation at 488 nm
(blue laser) and emission at 530/30 nm at a detector voltage of 373 V;
RFP, excitation at 561 nm (yellow-green laser) and emission at 586/15
nm at a detector voltage of 500 V; DAPI, excitation at 405 nm (violet
laser) and emission at 450/50 nm at a detector voltage of 302 V. In
order to calculate the weighted mean fluorescence intensity (MFI) for
red (early) and green (late) expression, the cell number (N) and mean
fluorescence (I) of quadrant 1 (Q1) (red cells), Q2 (red and green
cells), and Q4 (green cells) were inserted into the following formulas:
MFI(red)
(NQ1 IQ1) (NQ2 IQ2)
(NQ1 NQ2 NQ4)
MFI(green)
(NQ2 IQ2) (NQ4 IQ4)
(NQ1 NQ2 NQ4)
EVGR expression of all constructs was normalized to that of the Dun-
lop strain (set as 100%), and LVGR expression was normalized to that of
the archetype ww(1.4) (set as 100%). The mean values and standard de-
viations were calculated by Graph Pad Prism 6 (Mac OS).
Transfection of BKPyV genome into COS-7 and RPTECs and infec-
tion of RPTECs. Transfection of QIAamp DNA kit-purified BKPyV ge-
nomes into cells was initiated by cutting BKPyV plasmid DNA with
BamHI and religating the diluted DNA as described previously (18).
Transfection of religated BKPyV genomic DNA into COS-7 cells was per-
formed at 90 to 95% confluence in 6-well plates using Lipofectamine 2000
(11668-019; Invitrogen, Carlsbad, CA) or GeneExpresso 8000 (EG-1074;
Excellgen Inc., Gaithersburg, MD) at a reagent/DNA ratio of 3:1 accord-
ing to the manufacturers’ instructions. At 4 h after transfection, medium
was replaced with DMEM-H containing 2% fetal calf serum (FCS). At 14
days posttransfection, COS-7 cells were harvested by scraping off cells in
1/10 of the cell culture supernatant. Virus was released by 3 cycles of
freeze-thawing of the cells and centrifugation at 800 g for 5 min. Trans-
fection of religated BKPyV genomic DNA into RPTECs was performed at
90 to 95% confluence in 6-well plates using ViaFect transfection reagent
(E4982; Promega, Madison, WI, USA) at a reagent/DNA ratio of 3:1 ac-
cording to the manufacturers’ instructions. At 24 h after transfection,
medium was replaced with supplemented EpiCM medium (ScienceCell
Research Laboratory, Carlsbad, CA, USA). At 1, 2, 3, 5, and 7 days post-
transfection, 1 ml of supernatant for quantification of viral load was taken
and RPTECs were harvested by scraping off cells for Western blotting. For
the reinfection of RPTECs with COS-7 supernatants, cells were seeded at
75,000 cells per well of a 24-well plate in 0.5 ml of supplemented EpiCM
medium. After 24 h at a confluence of approximately 50%, RPTECs were
exposed to 200 l of the corresponding virus preparations at 37°C for 2 h
followed by removal, washing, and replacement with supplemented
EpiCM medium.
Determination of BKPyVviral loads by real-timePCR.BKPyV loads
were quantified after DNA extraction from 100 l cell culture superna-
tants with the Corbett X-tractor Gene and the Corbett VX reagents (Qia-
gen, Hombrechtikon, Switzerland). The real-time PCR protocol for de-
tection of BKPyV DNA samples targets the BKPyV large T-coding
sequence and has been described elsewhere (30).
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Immunofluorescence and antibodies. Five, seven, and 14 days
postinfection, RPTECs were fixed with 4% paraformaldehyde in phos-
phate-buffered saline (PBS) for 20 min and permeabilized with 0.2% Tri-
ton in PBS for 10 min at room temperature (8). After incubation with
monoclonal mouse anti-simian virus 40 (SV40) large T antigen (1:50;
DP02; Merck, Darmstadt, Germany), monoclonal mouse anti-VP1
(1:300; 10309-5E6; Abnova, Taipei City, Taiwan), and polyclonal rabbit
anti-agnoprotein (1:800) (31), diluted in 3% skim milk-PBS at 37°C for 1
h, cells were washed twice with PBS at room temperature for 5 min and
incubated with the secondary antibodies anti-mouse IgG1–Alexa Fluor
647 (1:800; A-21240; Life Technologies, Carlsbad, CA, USA), anti-mouse
IgG2a–Alexa Fluor 568 (1:300; A-21134; Life Technologies), and anti-
rabbit IgG–Alexa Fluor 488 (1:1,000; A-21441; Life Technologies) and
Hoechst 33342 dye (0.5 g/ml; H21492; Life Technologies) as described
for primary antibodies. After two washes, specimens were mounted in
90% glycerol (1.04095; Merck) in PBS containing 1% N-propylgallate
(P-3130; Sigma) as an antifading agent or ProLong Gold antifade reagent
with 4=,6-diamidino-2-phenylindole (DAPI; P36935; Life Technologies).
ww(1.4) P68 Q39 R63 S63O143 376
BKPyV
large T-ag
small T -ag
agno
VP1
VP3
VP2
NCCR
EVGR LVGR
Dunlop 387S63O142 P68 P50 P64
ins(7.3) O142 P68 P32 R63 S63Q39 407
del(5.3) O142 P68 Q25 S64R17 316
= NF1
= LTag
= Sp1
= NFkB
= c-Fos
= Ap1 = GM-CSF
= IL-6 pro.
= GRE
= PEA3= CMV-ie1
= Ap2 = Ets-1
= p53
= c-Jun
= Oct-1= CREB-2
= YY-1= ERE
= TATA box
del(15.10) O142 P68 Q13 S63R40 326
293del(13.8) P68 Q39 R3 S41O142
A
FIG 1 Schematic representation of BKPyV genome. (A) The early viral gene region (EVGR), encoding large and small T antigen (Tag), the late viral gene region
(LVGR), encoding capsid proteins (VP1, -2, and -3) and agnoprotein (agno), and the noncoding control region (NCCR). The NCCR of the archetype BKPyV
ww(1.4) and the rearranged rr-NCCRs found in Dunlop, in natural ins(7.3), del(5.3), del(15.10) variants, and in the del(13.8) variant from kidney transplant
patients with nephropathy are divided into sequence blocksO, P,Q,R, and S (subscript numerals are numbers of base pairs; total base pairs are on the right). The
colored symbols indicate predicted transcription factor binding sites (TFBS) according to the legend. (B) Flow cytometry and quantification of indicated NCCRs
cloned into the bidirectional reporter vector pHRG. x axis, GFP fluorescence; y axis, RFP fluorescence. For each measurement, 5,000 transfected (fluorescent)
cells were gated except for mock transfection, where 10,000 untransfected cells were measured. Numbers in the quadrants (Q) are absolute numbers of detected
cells and percentages with respect to the gated cells. Ex., excitation wavelength; Em., emission wavelength. (C) Summary plot. Red bars, sum of red cells
(Q1Q2); green bars, sum of green cells (Q2Q4); yellow bars, double-positive cells (Q2). (D) Normalized mean fluorescence intensity (MFI). For each
measurement, the weighted MFI was calculated (see Materials and Methods); late expression was normalized to theww(1.4) value (green MFI 100%), and early
expression was normalized to the Dunlop value (red MFI 100%). Quantification results are from 3 independent replicates.
Bethge et al.
3398 jvi.asm.org March 2015 Volume 89 Number 6Journal of Virology
Microscopy and digital image processing. Microscopy was per-
formed using an epifluorescence microscope (model TE200; Nikon)
equipped with suitable filters and a digital camera (Hamamatsu). DAPI-,
LTag-, VP1-, and agnoprotein-positive cells were counted in a minimum
of three microscopic fields (10 objective). Images were taken at the
times indicated in the figure legends. Digital images were recorded
with Openlab 2.2 software, and raw images were processed in Fiji
(version 1.49e).
Western blotting.Cells were lysed in NP-40-buffer (150 mM NaCl, 50
mM Tris-HCl [pH 8.0], 1% NP-40, and protease inhibitors [Roche]). Cell
lysates were separated by SDS-PAGE and electrotransferred onto
0.45-m Immobilon-FL polyvinylidene difluoride (PVDF) membrane
(IPFL00010; Millipore/Merck, Darmstadt, Germany). Membranes were
blocked with Odyssey blocking buffer (927-40000; Licor, Lincoln, NE,
USA) diluted 1:2 in Tris-buffered saline (TBS). The membrane was incu-
bated with the following primary antibodies: polyclonal rabbit anti-LTag
(1:5,000), polyclonal rabbit anti-VP1 (1:10,000), polyclonal rabbit anti-
agnoprotein (1:10,000), and monoclonal mouse anti-actin (1:5,000; Ab-
cam, Cambridge, England) in Odyssey blocking buffer–TBS– 0.1% Tween
20. Washing was performed with TBS– 0.1% Tween 20. Secondary anti-
bodies were donkey anti-mouse Alexa Fluor 680 (A10038; Invitrogen,
Life Technologies, Carlsbad, CA, USA) and goat anti-rabbit antibody–
IRDye 800CW (926-32211; Licor); both were used at a 1:10,000 dilu-
tion. Detection and quantification were done with the Licor Odyssey
CLx system.
EMSAs. Electrophoretic mobility shift assay (EMSA) analysis of
TFBS was performed as described previously (32). Briefly, 10 g of
nuclear extract from RPTEC cells was mixed with binding buffer [20
mM piperazine-N,N=-bis(2-ethanesulfonic acid) (PIPES), pH 6.8; 50
mM NaCl; 1 mM dithiothreitol (DTT); 0.25 mg/ml bovine serum al-
bumin (BSA); 100 M ZnSO4; 0.05% NP-40; 4% Ficoll] and approx-
imately 5 fmol of 32P-labeled, duplexed oligonucleotide in a final vol-
ume of 20 l (Table 1). Nuclear extracts were prepared as described by
Schreiber et al. (33) by scraping cells with ice-cold PBS off 10-cm
dishes and collecting them in Eppendorf tubes. After centrifugation,
they were swollen in hypotonic buffer (10 mM HEPES, pH 7.9; 10 mM
FIG 1 continued
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KCl; 0.1 mM EDTA; 2.5 mM DTT) and lysed by addition of NP-40
(final concentration, 0.5%). After centrifugation of the nuclei, pro-
teins were extracted in nuclear extract buffer (20 mM HEPES, pH 7.9;
25% glycerol; 400 mM NaCl; 1 mM EDTA; 2.5 mM DTT). Competing,
unlabeled oligonucleotides were used in a 200-fold excess. Transcrip-
tion factors were identified by supershifts. Specific antibodies to Sp1
(200 ng; SC-59; Santa Cruz Biotechnology), to NF-1 (200 ng; SC-5567;
Santa Cruz Biotechnology), to Ets1 (200 ng; SC-22802; Santa Cruz
Biotechnology), or to PEA3 (200 ng; SC-166629; Santa Cruz Biotech-
nology) were added to the binding buffer. After incubation of the
mixture on ice for 30 min, samples were separated on a native 4%
polyacrylamide gel with 0.25 Tris-borate-EDTA (TBE) as the run-
ning buffer. The detection of -decay was carried out with a Fujifilm
FLA-7000 Image plate reader.
RESULTS
To investigate the role of TFBS in archetype and rearranged
BKPyV NCCRs, two different computer prediction programs
were used with moderate stringency to locate major TFBS in silico.
In the archetype (ww) NCCR, approximately 30 TFBS were con-
sistently predicted by both programs and included multiple sites
for some factors like Sp1 or NF1 (Fig. 1). In rearranged (rr)-
NCCRs like the one found in clinical BKPyV variants from kidney
transplant patients with nephropathy (8, 24) or in the laboratory-
adapted Dunlop strain BKPyV-DUN (34), various TFBS were du-
plicated, deleted, and/or replaced (Fig. 1). Typically, the continu-
ity of the O143-P68 segment bearing the viral origin of replication
and the early TSS remained intact in the rr-NCCRs, but complete
or partial duplications of theP68 block were observed [ins(7.3) and
DUN] (Fig. 1A). Conversely, deletions in clinical rr-NCCRs typi-
cally affected the Q39-R63-S63 sequence blocks around the late TSS
TABLE 1 Oligonucleotides used for electrophoretic mobility shift assays
Name Sequence (5=¡3=)
Sp1 Promega fw ATT CGA TCG GGG CGG GGC GAG C
Sp1 Promega rev G CTC GCC CCG CCC CGA TCG AAT
Sp1-1 fw GGA GGC AGA GGC GGC CTC GGC CTC
Sp1-1 rev GAG GCC GAG GCC GCC TCT GCC TCC
Sp1-1 mut fw GGA AAC ATA TCC ATC CTA GGC ATC
Sp1-1 mut rev GAT GCC TAG GAT GGA TAT GTT TCC
Sp1-2 fw AGG CCA CAG GGA GGA GCT GCT TA
Sp1-2 rev TA AGC AGC TCC TCC CTG TGG CCT
Sp1-2 mut fw AGG CCA CAG TTA TGA GCT GCT TA
Sp1-2 mut rev TA AGC AGC TCA TAA CTG TGG CCT
Sp1-4 fw ATA GTG AAA CCC CGC CCC TGA AA
Sp1-4 rev TT TCA GGG GCG GGG TTT CAC TAT
Sp1-4 mut fw ATA GTG AAA CCG ATA CCC TGA AA
Sp1-4 mut rev TT TCA GGG TAT CGG TTT CAC TAT
Sp1-3/NF1-2 fw GCA TGA CTG GGC AGC CAG CCA GT
Sp1-3/NF1-2 rev AC TGG CTG GCT GCC CAG TCA TGC
Sp1-3/NF1-2 mut fw GCA TGA ACA TGC AAC CAG CCA GT
Sp1-3/NF1-2 mut rev AC TGG CTG GTT GCA TGT TCA TGC
Sp1-4 5CG fw ATA GTG AAA CCC GGC CCC TGA AA
Sp1-4 5CG rev TT TCA GGG GCC GGG TTT CAC TAT
Sp1-4 5CG/10CT fw ATA GTG AAA CCC GGC CCT TGA AA
Sp1-4 5CG/10CT rev TT TCA AGG GCC GGG TTT CAC TAT
Sp1-4 10CT fw ATA GTG AAA CCC CGC CCT TGA AA
Sp1-4 10CT rev TT TCA AGG GCG GGG TTT CAC TAT
Sp1-4 7CG/10CT fw ATA GTG AAA CCC CGG CCC TGA AA
Sp1-4 7CG/10CT rev TT TCA GGG CCG GGG TTT CAC TAT
Ets1-2 fw ACA CAA GAG GAA GTG GAA ACT G
Ets1-2 rev C AGT TTC CAC TTC CTC TTG TGT
Ets1-2 HI-u6/CAP-m5 fw ACA CAA GAG GGA GTG GAA ACT G
Ets1-2 HI-u6/CAP-m5 rev C AGT TTC CAC TCC CTC TTG TGT
Ets1-2 15.10 fw ACA CAA CAG GAA GTG GAA ACT G
Ets1-2 15.10 rev C AGT TTC CAC TTC CTG TTG TGT
ets1-2 fw ACA CAA TAT TAA GTG GAA ACT G
ets1-2 rev C AGT TTC CAC TTA ATA TTG TGT
A
1 ww(1.4)
sp1-23
sp1-12
sp1-4a4
sp1-4b5
6 sp1-(1,2,4a)
7 yy1-1*sp1-2
8 nf1-1
9 nf1-2
10 nf1-3
11 nf1-4
12 nf1-5
13 nf1-(1,3,5)
14 yy1-1*nf1-1
15 ets1-2
16 p53
17 yy1-1
18 ltag(1,2)
19 ltag(3,4)
1 100 200 300 376
P(68) Q(39) R(63)O(143) S(63)
P(68) Q(39) R(52)O(143) S(63)
20
del(R8-18)
*sp1-(1,2,4a)21
*nf1-(1,3,5)22
*ltag(1,2)23
1 100 200 300 365
*ltag(3,4)24
B
C
sp1-(2,4a)26
25
27
28
sp1-(1,4a)
1 100 200 300 376
sp1-2*ets1-2
sp1-4a*ets1-2
P(68) Q(39) R(63)O(143) S(63)
FIG 2 Mutant BKPyV NCCRs. The mutant NCCR sequences (see Table S1 in
the supplemental material) are named according to mutant site (italics) and
represented by colorless symbols with dashed lines, and they were tested for
early (EVGR) and late (LVGR) gene expression in the bidirectional reporter
pHRG. (A) Mutant NCCRs introduced into archetype ww(1.4)-NCRR. (B)
Mutant NCCRs introduced into the rr-NCCR carrying a 11-bp deletion in the
R block (R8–18). (C) Dual TFBS mutants.
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[del(5.3), del(15.10), del(13.8), and DUN] (Fig. 1A). To experi-
mentally quantify the effect on viral gene expression, the rr-NCCR
variants and the ww-NCCR were cloned into the reporter gene
vector pHRG, which, as reported earlier (8), recapitulates the bi-
directional organization of the polyomavirus DNA genome and
allows monitoring of NCCR-directed EVGR and LVGR expres-
sion by the red fluorescent protein (RFP) and the enhanced green
fluorescent protein (eGFP), respectively. The corresponding
NCCR reporter constructs were transfected into the embryonic
kidney cell line HEK293. As shown in Fig. 1B, the archetype ww-
NCCR conferred strong LVGR and weak EVGR expression, as
indicated by the respective red and green signals detected by flow
cytometry. In contrast, the rr-NCCR of BKPyV-DUN and all of
the clinical rr-NCCR variants showed an opposite pattern, with
strong EVGR expression in red but weak LVGR expression in
green (Fig. 1B). Quantification showed that, compared to ww-
NCCR, rr-NCCR increased both the number of cells expressing
the EVGR as well as the mean fluorescence intensity (MFI) of
EVGR expression in the cells (Fig. 1C and D). Despite the respec-
tive dominance of LVGR or EVGR expression, both the archetype
and the rearranged NCCR pattern showed limited expression in
the respective opposite direction within the same single cells (Fig.
1C, yellow bars). Moreover, although increased EVGR expression
was clearly the common hallmark of the clinical rr-NCCRs, the
quantitative results indicated that there were differences between
the various clinical rr-NCCR variants with respect to EVGR and
LVGR levels (Fig. 1D). However, the diversity in TFBS content,
the altered OPQRS architecture, and the overall length of the clin-
ical rr-NCCR variants (Fig. 1A) did not point to an obvious hier-
archy of TFBS or their role in BKPyV EVGR and LVGR expres-
sion.
To dissect the potential role of various TFBS, we introduced
point mutations into the archetypeww-NCCR that were predicted
to abrogate binding of respective proteins. Importantly, the over-
all architecture and length of 376 bp of the archetype ww-NCCR
remained unaltered (Fig. 2A; for sequences, see the supplemental
material). Additionally, some TFBS mutants were either com-
bined with other TFBS mutations (Fig. 2A and C) or placed in the
background of the experimentally designed rr-NCCR del(R8–18)
deletion mutant described previously (8) (Fig. 2B) to investigate
their effect in a defined deletion background known to activate
EVGR expression.
The resulting mutant ww-NCCRs were placed in the bidirec-
tional reporter gene vector pHRG, and the reporter constructs
were verified by sequencing, and transfected into HEK293 cells.
RFP and GFP expression was detectable at 1 day posttransfection
(dpt) and persisted for at least 5 days (not shown). Analysis of the
EVGR and LVGR reporter gene expression revealed that the TFBS
mutant ww-NCCRs could be grouped into three phenotypic
groups (Fig. 3).
Group 1 mutants were exemplified by the prototype mutant
with a sp1-4a mutation of the SP1-4 site and characterized by
stronger EVGR than LVGR expression (Fig. 3). Thus, the group 1
mutants resembled the clinical rr-NCCR BKPyV variants from
kidney transplant patients with nephropathy (Fig. 1). Although
EVGR expression was dominant, some LVGR expression still oc-
curred, as shown by the cells that were positive for both RFP and
GFP (Fig. 3C, yellow bars).
Group 2 mutations exemplified by the prototype nf1-4 mutant
also showed an increased EVGR signal but a lesser reduction of
LVGR expression of the archetype signal compared to group 1
mutations (Fig. 3). This was reflected in a higher number of
LVGR-expressing cells (Fig. 3C) and a higher green MFI (Fig. 3D).
Group 3 mutations were exemplified by the prototype sp1-2
mutant and characterized by reduced green LVGR expression
compared to that of the parent archetype ww-NCCR, but, unlike
in group 1 and group 2 mutants, the red EVGR expression was not
increased (Fig. 3).
The group 1 phenotype was also observed by a different muta-
tion similarly predicted to inactivate the SP1-4 (called sp1-4b) in
the Q39 block and by an inactivating mutation of the ETS1-2 site
(called ets1-2) in the R63 block (Fig. 4A; also, see the sequences in
Table S1 in the supplemental material). Comparison with the clin-
ical rr-NCCR variants suggested that these point mutations at
least partly explained the phenotype seen in the clinical rr-NCCR
variants bearing deletions: in the del(15.10) NCCR, SP1-4 was
missing, in the del(13.8) NCCR, ETS1-2 was missing, and both
sites were missing in the del(5.3) NCCR.
The group 2 phenotype was seen to result from single TFBS
mutations targeting p53, yy1, and different NF1 sites (called nf1-2,
nf1-3, nf1-4, and nf1-5, from early to late TSS) and from the dual
mutation ltag(3,4) (Fig. 4B). Group 2 mutations showed an in-
creased EVGR expression relative to the archetype ww(1.4), but
LVGR expression appeared to be less impaired than observed for
the group 1 mutations (Fig. 4B). The intermediate group 2 phe-
notype suggested that the group 1 TFBS targets SP1-4, and ETS1-2
TFBS were essential for LVGR expression, whereas group 2 TFBS
had a modulatory role. Interestingly, the nf1 mutations seemed to
have subtle differences with increasing EVGR expression, as the
mutated sites were located further from the early TSS and closer to
the late TSS (Fig. 4B).
Group 3 mutations resulted in an overall reduced LVGR and
EVGR expression and included other Sp1 TFBS, called sp1-1 and
sp1-2, located close to the early TSS, nf1-1, and ltag(1,2), as well as
their yy1*sp1-2, sp1-(1,2,4a), nf1-(1,3,5), del(R8–18)*sp1-(1,2,4a),
del(R8–18)*nf1-(1,3,5), and del(R8–18)*ltag(1,2) combination mu-
tants (Fig. 4C). Thus, with the exception of the sp1-1, sp1-2, and
nf1-1 mutants, all other group 3 mutants targeted more than one
site in the NCCR. Accordingly, some of these combinations
shifted the expression from a group 2 to a group 3 pattern, e.g., for
yy1 when combined with sp1-2, as in the yy1*sp1-2 mutant, or
with nf1-1, as in the yy1*nf1-1 mutant (Fig. 4C). Most promi-
nently, the EVGR activation of the group 1 mutation sp1-4a was
reversed as was the sp1-(1,2,4a) triple mutation (Fig. 4C). Also, the
activating background of the del(R8–18) mutant was reversed,
when combined with the mutation sp1-(1,2,4a), nf1-(1,3,5), or
ltag(1,2). This suggested that some TFBS, such as SP1-1 or SP1-2,
were of particular importance to the overall bidirectional promot-
er/enhancer function of the BKPyV NCCR.
To investigate the role of Sp1 in more detail, several additional
TFBS mutants were generated and analyzed (Fig. 4D). Combining
the inactivation of SP1-4 and SP1-1 in the sp1-(1,4a) NCCR
showed a reduction of LVGR expression (characteristic of sp1-4a)
and a reduction of EVGR expression (characteristic of sp1-1), in-
dicating that either site had an independent contribution to viral
gene expression (Fig. 4D). The same was observed for the combi-
nation of sp1-2 and sp1-4a in sp1-(2,4a). The independent contri-
bution of each of these Sp1 sites was supported by the further
decrease observed for the triple combination sp1-(1,2,4a). Simi-
larly, sp1-2 also decreased EVGR expression when combined with
Sp1 controls early and late BKPyV gene expression
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FIG 3 Phenotypic characterization of NCCR point mutations. (A) The indicated constructs were transfected into HEK293 cells, and fluorescence images (20
objective) were taken 2 days posttransfection (dpt). The archetype ww(1.4) strain and the Dunlop strain served as references. The group 1 prototype is sp1-4a
(high early and low late expression), the group 2 prototype is nf1-4 (intermediate to high early and intermediate late expression), and the group 3 prototype is
sp1-2 (low early and low to intermediate late expression). (B) Plots of representative FACS measurements of indicated NCCRs in HEK293 at 2 dpt as described
in Fig. 1. (C) Cell counts of red, green, and double-positive cells. (D) Weighted mean fluorescence intensity (MFI) (Fig. 1).
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ets1-2, as in the sp1-2*ets1-2 double mutant. Taken together, the
data suggested that the different Sp1 sites played an important
independent role in the control of BKPyV EVGR and LVGR ex-
pression. The pronounced inactivating effect of the group 3 mu-
tations sp1-1, sp1-2, nf1-1, and ltag(1,2) also suggested an expla-
nation for why deletions have not been observed in the O143-P68
block of prominent clinical rr-NCCR variants, wherein these sites
are located (Fig. 1).
Given the substantial effects of the ww-NCCR point mutations
on EVGR and LVGR reporter expression, it was of interest to
study their consequences for BKPyV replication. To that end,
group 1 sp1-4a and ets1-2 mutant NCCRs were placed in the
BKPyV backbone and transfected into primary human renal
proximal tubule epithelial cells (RPTECs). Compared to the ar-
chetype (ww) NCCR BKPy, a rapid increase in supernatant viral
loads was seen for the del(5.3) NCCR BKPyV (Fig. 5A). Both
group 1 mutants, the sp1-4a- and ets1-2 NCCR BKPyV recombi-
nants, also replicated significantly faster than the archetype but
more slowly than the natural variant del(5.3) NCCR BKPyV over 7
days posttransfection (dpt) (Fig. 5A). Group 1 mutants showed
enhanced early and late viral gene expression compared to the
archetype, although this was less than in the clinical variant
del(5.3)-bearing virus, as immunofluorescence (Fig. 5B) or im-
munoblots (Fig. 5C) showed LTag and VP1 expression being
highest for del(5.3), followed by sp1-4a, ets-2, and then the
ww-NCCR virus.
To compare the replication of different recombinant NCCR
mutant viruses over time, supernatant BKPyV loads were deter-
mined over 7 dpt and 13 dpt (Fig. 6A). As expected, supernatant
viral loads of the del(5.3) and DUN NCCR had increased by more
than 1,000-fold by 7 dpt. The group 1 mutations sp1-4a and ets1-2
replicated slightly less efficiently than the natural del(5.3) variant
but better than the archetype virus, a difference that became more
evident by 13 dpt. In contrast, the group 3 mutations sp1-2 and
sp1-1 as well as sp1-(1,2,4a) permitted only little or no replication
of the respective recombinant BKPyV mutant viruses (Fig. 6A).
To investigate the infectivity of the mutant ww-NCCR viruses,
COS-7 cells were transfected, and the respective supernatants
were used to infect primary human RPTECs. At 7 days postinfec-
tion (dpi), the archetypeww(1.4) NCCR virus displayed only a few
cells that were positive for LTag in the nuclei and agnoprotein in
the cytoplasm (Fig. 6B). Instead, the del(5.3) and DUN NCCR
viruses abundantly expressed the early LTag and the late agnopro-
tein, as reported previously (8). Group 1 mutant sp1-4a and
sp1-4b NCCR viruses showed increased infectivity compared to
the archetype, whereas the group 2 and group 3 mutations re-
sulted in few and no infected cells, respectively. In particular, sp1-1
and sp1-(1,2,4a) mutations seemed to result in virtually undetect-
able infectivity. Overall, infection and replication matched the
bidirectional phenotypic reporter assay rather well.
Given the prominent effect of mutating the predicted Sp1 sites
FIG 4 Summary of mutant NCCR phenotype groups. The indicated mutant
NCCR bidirectional reporter constructs were transfected into HEK293 cells
and grouped according to normalized MFI (Fig. 1D) (see Materials and Meth-
ods). (A) Group 1 NCCR mutants (high early expression and low late expres-
sion). (B) Group 2 NCCR mutants (intermediate early and late expression).
(C) Group 3 NCCR mutants (low early and low intermediate late expression).
(D) MFI comparison of single-site mutants with selected double and triple
mutants.
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on EVGR and LVGR expression, Sp1 binding to the archetype and
the mutant sequences was examined by electrophoretic mobility
shift assay (EMSA) (Fig. 7). For the archetype-derived oligonucle-
otides bearing the wild type SP1-1, SP1-2, and SP1-4 TFBS (Table
1), a similar band shift pattern was observed, that was reduced in
the presence of unlabeled oligonucleotides bearing the Sp1 con-
sensus sequence (Fig. 7A). Addition of an Sp1-specific monoclo-
nal antibody (Sp1 MAb) caused a supershift, confirming the iden-
tity of the bound factor. For oligonucleotides bearing the putative
SP1-3 site, however, a different EMSA pattern was obtained,
which could neither be competed with a consensus SP1-oligonu-
cleotide sequence nor be shifted with the Sp1 MAb. Instead, bind-
ing of NF1 was documented through competition by an unlabeled
oligonucleotide containing the NF1 consensus sequence and a su-
FIG5 Replication and protein expression of recombinant NCCR BKPyV. (A) RPTECs were transfected with the indicated recombinant BKPyV NCCR genomes.
Supernatant viral loads were quantified by quantitative PCR after 1, 2, 3, 5, and 7 days posttransfection (dpt). Increases in BKPyV supernatant viral loads are
expressed on a log scale. (B) Immunofluorescence was performed for large T antigen (LTag; red), agnoprotein (agno; green), and viral protein 1 (VP1; cyan) at
7 dpt. The nuclei are marked with DAPI (blue). The graph shows expression of the indicated viral proteins relative to that of the archetype ww(1.4) protein. (C)
Western blot of indicated cell extracts showing LTag (triangles) and VP1 in green (triangles); actin (red) served as a loading control. Actin-normalized band
fluorescence intensity (bottom diagrams) was quantified using Licor Image Studio, with ww(1.4) as a reference.
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pershift induced by NF1-specific antibody (Fig. 7A). This site cor-
responded to nf1-2. Thus, all point mutations in fact led to a sig-
nificant reduction or loss of the respective transcription factor
binding activity in the EMSA (Fig. 7A), which is an important
finding for the interpretation of the reporter assay results.
Since the sp1-4 mutations significantly increased EVGR ex-
pression and BKPyV replication similarly to natural rr-NCCR
variants found in kidney transplant patients, database entries were
searched for sequence alterations affecting this specific site. In-
deed, in a study of bone marrow transplant patients with hemor-
rhagic cystitis, overrepresentation of sp1-4 mutations in clinical
BKPyV variants had been described (27) (Fig. 7B, top). Testing the
effect of these mutations on Sp1 binding by EMSA revealed a
reduced Sp1 binding for the mutations 5CG, 5CG/10CT, and
FIG 6 Replication and infectivity of BKPyV NCCR mutant strains. (A) RPTECs were transfected using the indicated recombinant BKPyV NCCR variants.
Supernatant viral loads quantified by quantitative PCR after 1, 7, and 13 days posttransfection (dpt). The increase in supernatant viral loads was normalized to
the value at 1 dpt. (B) Supernatant taken from COS-7 cells at 14 dpt were used to infect RPTECs. Immunofluorescence was performed to detect large T antigen
(LTag; red) and agnoprotein (agno; green) at 7 days postinfection; cell nuclei are in blue.
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7CG/10CT (Fig. 7B). The data lend support to the notion that
sp1-4 mutations reducing Sp1 binding are found in clinically rel-
evant BKPyV diseases.
EMSA was also performed for the ETS1-2 site. The labeled
archetype sequence showed binding by mobility shift (Fig. 7C),
whereas no binding to the group 1 mutant ets1-2 sequence was
seen (Fig. 7C, rightmost lanes). Addition of a monoclonal Ets1
antibody induced a supershift, while antibodies to Sp1 or to PEA3,
another Ets family member, had no effect (Fig. 7C). This indicated
that ETS1-2 contained an Ets1-binding site that was abrogated by
the respective group 1 point mutations. As indicated above (Fig.
1A), ETS1-2 was found to be deleted in the natural rr-NCCR
BKPyV variants from kidney transplant patients with nephropa-
thy, e.g., together with the SP1-4 site in the del(5.3) mutant and in
the del(13.8) mutant (8). In another natural rr-NCCR variant, the
del(15.10) variant, (8), a deletion of the SP1-4 site occurred to-
gether with a point mutation that was predicted to change the
archetype BKPyV ETS1-2 site to a perfect Ets1 consensus. Indeed,
EMSA revealed strong binding to the mutated Ets1 site found in
the del(15.10) NCCR sequence that could be supershifted by Ets1
antibody but not by PEA3 antibody, and the unlabeled del(15.10)
sequence was an effective competitor for the archetypeww-NCCR
sequence (Fig. 7C). Interestingly, the del(15.10) NCCR showed a
group 2 rather than a group 1 phenotype (8). This is in line with
the notion that both the SP1-4 and the ETS1-2 TFBS conferred
independent regulation on EVGR and LVGR and that loss of the
SP1-4 was partially counteracted by stronger Ets1 binding (Fig.
7D). A database search revealed that the ETS1-2 site was altered in
two clinical cases with significant BKPyV disease. The first case
was an HIV-1 infected patient with BKPyV-associated hemor-
rhagic cystitis (29). Here, the mutant ets1-2 sequence was pre-
dicted to abrogate Ets1 binding, while a novel Sp1 site was poten-
tially created. Indeed, the corresponding sequences showed a
changed mobility pattern, as determined by EMSA, that could no
longer be supershifted by an antibody to Ets1 but could be super-
shifted by the Sp1 MAb (Fig. 7C). The other case was a kidney
transplant patient with nephropathy, who developed a general-
ized capillary leak pathology with fatal outcome (28). The BKPyV
genome showed no evidence of NCCR rearrangements, but a
point mutation in ETS1-2 (29). Our results now indicate that this
mutation abrogates Ets1 binding similarly to the group 1 muta-
tion generated experimentally, causing an activated EVGR expres-
sion. To evaluate the effect on EVGR and LVGR expression, the
corresponding mutant NCCRs were placed into the pHRG and
analyzed by flow cytometry (Fig. 7D). The results show that the
clinically occurring point mutations result in increased EVGR ex-
pression compared to the archetype ww-NCCR, as expected for
group 1 and 2 mutants.
DISCUSSION
The NCCR represents less than 10% of PyV genomes but effec-
tively mediates key functions of polyomavirus biology inside the
host cell. This includes silent persistence of the episomal viral ge-
nome and the appropriately timed (re)activation of the PyV life
cycle, consisting of EVGR expression followed by viral genome
replication and LVGR expression to generate infectious progeny.
Besides a principle virological interest in the mechanisms mediat-
ing these functions within less than 400 base pairs (35), there is a
strong clinical interest, since NCCR rearrangements have been
associated with major human PyV pathologies, i.e., BKPyV-asso-
ciated nephropathy and JCPyV progressive multifocal leukoen-
cephalopathy (8, 13, 18, 25, 36, 37) and more recently an HPyV-
7-associated proliferative keratinocytic skin disease (38).
However, the multitude of TFBS and their considerable diversity
in clinically identified NCCR rearrangements has hampered
identification of their specific role in PyV biology and human
pathology.
The discrete mutational analysis of the BKPyV archetype
NCCR in this study now indicates that the basal bidirectional
EVGR and LVGR expression is critically controlled by a hierarchy
of TFBS, which can give rise to at least three phenotypic groups.
Group 1 mutations include sp1-4 and ets1-2 inactivating a single
Sp1 and a single Ets1 site close to the late TSS, respectively, and
redirect expression to the EVGR at the expense of LVGR expres-
sion. Thereby, group 1 mutations appear to be functionally similar
to previously characterized clinical rr-NCCR variants such as
del(5.3) (8). The group 1 mutant NCCRs are functional in the viral
genomic context, conveying increased LTag expression, higher
viral loads, and infectious virus progeny.
Group 2 mutations show an intermediate phenotype re-
garding EVGR and LVGR reporter gene expression as well as
viral replication rates. Group 2 mutations resulted from inac-
tivating different TFBS located in the central P68-Q39-R63 se-
quence blocks and appear to modulate the EVGR-LVGR ex-
pression balance. Combining different group 2 mutations did
not lead to a further increase in EVGR, suggesting that possibly
similar or converging modulating functions might be affected
by the respective TFBS mutations. In contrast, group 3 muta-
tions interfered more prominently with the net expression of
both EVGR and LVGR. Moreover, group 3 mutations were able
to revert the activating effect of some group 1 and 2 mutations,
suggesting the loss of an essential function required for gene
expression in both directions from the NCCR. This contribu-
tion was most strikingly impaired when sp1-1 and sp1-2 were
combined, which alone and in combination abrogated even the
EVGR-activating group 1 mutation sp1-4. The group 3 recom-
FIG 7 Binding of Sp1 and Ets1 to archetype and mutant NCCR sequences and reporter gene expression. (A) Electrophoretic mobility shift assays (EMSAs) were
performed using labeled and duplexed oligonucleotides carrying the indicated NCCR sequences with nuclear extracts (NUX) alone or in the presence of
unlabeled competitor (comp) or monoclonal antibody (MAb), where indicated. Names of oligonucleotides (top row) refer to putative binding sites; wt, wild type
sequence; mut, mutated binding site; NUX, 10 g of RPTEC nuclear extract; comp, competition with 1 pmol unlabeled oligonucleotide with Sp1 or NF1
consensus sequence; MAb, 200 ng of monoclonal Sp1 or NF1 antibody for supershift; FP, free probe. (B) (Top) Alignment of naturally occurring SP1-4 mutants
as described by Priftakis et al. (27). Names refer to the position relative to the SP1-4 binding site start and type of exchange. (Bottom) Binding analysis of SP1-4
mutants. (C) Oligonucleotides bearing the indicated archetype or mutant NCCR sequences were incubated with nuclear extracts as described in Materials and
Methods. Archetype,ETS1-2 sequence from the BKPyVww(1.4) strain; HI-u6/CAP-m5, sequence derived from a natural variant found in a patient with systemic
BKPyV replication and capillary leak pathology (29); 15.10, sequence derived from a natural variant del(15.10) from kidney transplant patients with nephropathy
(8); NUX, 10g of RPTEC nuclear extract; MAb, 200 ng monoclonal Ets1, PEA3, or Sp1 antibody for supershift; FP, free probe. (D) The indicated mutant NCCR
bidirectional reporter constructs were transfected into HEK293 cells and grouped according to normalized MFI (Fig. 1D) (see Materials and Methods).
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binant viruses bearing the ww(sp1-1) and ww(sp1-2) NCCRs
permitted no or little replication and infectivity. Thus, the ar-
chetype BKPyV ww-NCCR is mediated by multiple TFBS with
differential abilities to direct, modulate, and facilitate EVGR
and LVGR expression, with corresponding effects on viral rep-
lication.
Earlier studies examined the role of different TFBS on BKPyV
EVGR or LVGR, but the most attention has been given to proto-
type strains bearing rearranged NCCR sequences. Moreover, the
experimental approaches relied exclusively unidirectional re-
porter gene analyses. This precluded the unique detection of a
loss-of-function phenotype for LVGR expression, resulting in a
gain of function for EVGR expression, as shown here for group 1
mutations. By linker scanning deletions, Cassill et al. and Deyerle
et al. identified a significant decline in LVGR reporter gene expres-
sion when a stretch presumably containing the SP1-2 site was
deleted, which would be consistent with the essential role of group
3 sp1-2 reported here (39, 40). For the rr-NCCR present in the
BKPyV Gardner strain, mutation of NCCR positions 147 to 156,
also corresponding to SP1-2, was reported to reduce early tran-
scription by 81%. Importantly, this SP1-2 deletion had no dra-
matic impact on mutant replication in COS-1 cells, which is able
to provide EVGR functions in trans from the SV40 LTag (41, 42),
similar to the COS-7 cells used for this purpose here. Markowitz
and Dynan identified strong binding of Sp1 to the SP1-4 site when
HeLa cell extracts were probed with the archetype ww-NCCR and
reported binding of NF1 to multiple sites of the BKPyV NCCR,
but they did not investigate functional aspects (43).
The hierarchy of TFBS revealed by our minimally disruptive
mutation analysis of the archetype ww-NCCR extends these ob-
servations and provides a new perspective on naturally occurring
NCCR mutants and their association with disease, where group 1
and group 2 sites are frequently altered (Fig. 1A) (8, 13, 26). The
role of group 1 TFBS is underlined by independent clinical reports
of Sp1-4 or Ets1-2 mutant NCCR variants in patients with signif-
icant disease, including hemorrhagic cystitis (27), nephropathy,
and fatal capillary leak pathology (28). The latter case is particu-
larly striking because of disseminated BKPyV infection taking a
fatal course in the absence of previously known viral determinants
(29). Our results provide the first experimental support for the
notion that regulatingETS1-2binding activates EVGR expression,
thereby conferring a functional equivalent to rr-NCCRs in this
specific case of BKPyV capillary leak pathology. Similarly, Prifta-
kis et al. (27) reported an overrepresentation of mutations at the
SP1-4 site which were associated with median urine viral loads
that were approximately 1 log10 Geq/ml higher than those in pa-
tients with archetype virus (27). Here, we show experimentally
that these previously reported sp1-4mutations reduce or abrogate
Sp1 binding and result in an activation of EVGR expression sim-
ilarly to our designed sp1-4a and sp1-4b mutations. The weakest
effect was seen with sp1-4(10CT), while the strongest appeared
with the double mutation sp1-4(7CG/10CT) (27), suggesting that
Sp1 affinity to the SP1-4 site might play a role. Interestingly, the
related JCPyV NCCR also bears an SP1-4-like site in the D block
close to the LVGR that is frequently lost in natural NCCR rear-
rangements in patients with progressive multifocal leukoenceph-
alopathy (18, 44, 45). Other TFBS proposed to contribute to
JCPyV EVGR activation include Spi-B, which is a member of the
Ets family (46–48).
A review of Sp1 and Ets1 literature suggests that these factors
act as versatile sensors of intrahost cell physiology and signaling
(49–51), which can be exploited by BKPyV for steering its viral life
cycle.
Ets1 was originally identified as the cellular proto-oncogene
counterpart to the retroviral oncogene v-ets (E26 transforming
sequence), which acts together with v-Myb protein in an avian
erythroblastosis retrovirus, E26. The Ets family has more than 30
members, including Ets2, Spi-B, Spi1/Pu1, PEA3, and Elk1 and -2,
and recognizes the 5=-GGAA/T-3= core motif, thereby integrating
responses in differentiation, proliferation, angiogenesis, and neo-
plasia, including in hematopoietic malignancies and prostate
cancer.
Sp1, originally called specificity protein 1, is one of at least
eight related Sp transcription factors that contain three C-ter-
minal cysteine2-histidine2-type zinc finger DNA-binding do-
mains (50, 51). Sp1 can either activate or repress the promoter
activity of genes involved in environmental, nutritional, and
hormonal responses (51, 52). This includes nuclear signaling
downstream of insulin, corticosteroids, androgen, estrogen,
parathyroid hormones and retinoic acid. Hormone receptor
signals are captured by Sp1 binding to a single TFBS followed
by superactivation involving Sp1 complexes and DNA looping
through recruiting more distal Sp1 sites (51, 53). The sequen-
tial recruitment of TFIID and RNA polymerase II by Sp1 has
also been linked to the efficient transcriptional initiation of
TATA-less genes (50, 54, 55), which in many cases actually
might be promoters with hidden TATA boxes in the form of
TATA-like elements (56). In the BKPyV ww-NCCR, SP1-4 and
ETS1-2 are located approximately 21 bp apart, forming a tran-
scription factor module. Similar synergistic activation by Sp1
and Ets1 sites has been reported for the long terminal repeat
(LTR) of the human T-cell leukemia virus type 1 (HTLV-1),
where Sp1 and Ets1 form a ternary complex with the proviral
DNA site and synergistically activate LTR-driven transcription
(57). We and other researchers have reported that the BKPyV
NCCR confers corticosteroid responses (8), which may explain
the role of corticosteroids as risk factors for BKPyV replication
and nephropathy beyond its immunosuppressive effects in kid-
ney transplant recipients (58–61). In renal cells, ischemia and
reperfusion have been linked to a lower Sp1 transcriptional
activity (62). Also, Sp1 activity in response to insulin increases
the expression of insulin receptor (51). It is therefore tempting
to speculate that Sp1 and Ets1 sites in the BKPyV NCCR mo-
lecularly direct and integrate viral responses when hypoxia,
ischemia/reperfusion injury, insulin resistance, and new-onset
diabetes, as well as inflammation and stress signals, are sensed
(58, 59, 63–65).
To summarize and integrate the experimental results, we
propose the following working model (Fig. 8), in which Sp1
and Ets1 provide directional impact for LVGR and EVGR ex-
pression and group 2 factors like NF1 modulate this direction-
ality. The model includes the TATA box for EVGR expression
as well as a TATA-like element close to the LVGR TSS bearing
mismatches (56), as suggested before (66, 67). Accordingly,
host cell signals leading to viral (re)activation, such as stress,
injury, or insulin signaling, can act by modulating Sp1 and Ets1
activity. Natural variants, including point mutations, dele-
tions, and duplications, facilitate activated EVGR expression at
the expense of LVGR. Thus, the EVGR-activating signals or
group 1 and group 2 mutations could be a first step toward
Bethge et al.
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generation of more replication-competent variants in patients
lacking sufficient immune responses (8, 18). Future studies
need to examine in more detail the molecular mechanism(s) by
which the NCCR rearrangements are generated. Presumably,
rearrangements occur as errors during recircularization of the
bidirectionally replicated polyomavirus DNA genome and se-
lect those variants that convey a replicative advantage in im-
munocompromised patients (8, 18, 68). In fact, the biological
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FIG 8 Working model summarizing bidirectional regulation from the BK polyomavirus NCCR. The transcription factors Sp1, Ets1, and NF-1 determine the
strength and direction of gene expression toward EVGR (early; red arrow) and LVGR (late; green arrow). (Top) The archetype ww(1.4) NCCR mediates basal
activity with low EVGR expression (dashed arrow) and high LVGR expression (green arrow). Sp1 and Ets1 contribute a directional effect on neighboring Sp1 and
Ets1, whereas NF1 has a stabilizing effect. (Center) Mutant NCCR phenotypes, according to EVGR and LVGR expression. The group 1 TFBS mediate a major
contribution of Sp1 or Ets1 to LVGR expression, which is abrogated in their absence and results in a net increase of EVGR expression. Group 2 TFBS stabilize Sp1
and Ets1 locally and thereby contribute to LVGR and EVGR expression in a partly position-dependent way. Group 3 TFBS are essential for EVGR and LVGR
expression, since in their absence, mutants show low viral expression. This suggests that binding to SP1-2 is of overall importance for EVGR and LVGR
expression, with possible implications for latency. (Bottom) Patient isolates with rr del(5.3) and ins(7.3) NCCRs result in part from group 1 and 2 mutant effects.
In addition, NF1 sites in the center of the NCCR may interfere in an insulator-like fashion with the presumed Sp1 action from SP1-2 on LVGR expression.
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plasticity of a functional NCCR repair has been demonstrated
in an experimental model of SV40 promoter rescue (69).
In conclusion, this study indicates that the basal BKPyV NCCR
is critically controlled by a hierarchy of single TFBS in the arche-
type NCCR that direct, modulate, and execute bidirectional
EVGR and LVGR expression. Our results provide new insights
into how BKPyV NCCR functions as a viral sensor of host cell
signals through TFBS, including Sp1, Ets1, and NF1. Future stud-
ies will demonstrate whether identical or similar hierarchy exists
in other human PyVs.
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